United States:
USPTO Extends Deadline For Comments On USPTO-FDA Collaboration Initiatives
07 March 2023
Goodwin Procter LLP
To print this article, all you need is to be registered or login on Mondaq.com.
On February 24, the
USPTO extended the written comment period for Joint
USPTO–FDA Collaboration Initiatives until March 10, 2023. As
we
previously reported, the USPTO requested public input on areas
for USPTO-FDA collaboration and engagement in response to President
Biden's Executive Order to "help ensure that the patent
system, while incentivizing innovation, does not also unjustifiably
delay generic drug and biosimilar competition beyond that
reasonably contemplated by applicable law." According to the
notice published in the Federal Register, the USPTO extended the
deadline "to ensure that all stakeholders have a sufficient
opportunity to submit comments on the questions presented" in
the earlier notice. Comments can be submitted through the Federal
eRulemaking Portal at this link –
Regulations.gov.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
USPTO Embraces AI Tools In New Guidance
Crowell & Moring LLP
On April 11, 2024, the USPTO published its "Guidance on Use of Artificial Intelligence-Based Tools in Practice Before the United States" in the Federal Register (the "Guidance"). As the title suggests...
Breaking Down The EPO's Revised Practice Guidelines
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
The guidelines for examination in the European Patent Office instruct on the practice and procedure related to the examination of European patent applications...
USPTO Issues Guidance On Use Of AI-Based Tools
Greenberg Traurig, LLP
On April 11, 2024, the U.S. Patent and Trademark Office (USPTO) issued Guidance on Use of Artificial-Intelligence-Based Tools (Guidance), which applies existing rules and policies...